However, if your logo-creating needs are simple, Hatchful’s offering could be for you. After running through the process, you'll come out the other side with high-resolution images suitable for ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Biogen (BIIB – Research Report) and keeping the price target at ...

Begin your TipRanks Premium journey today. Biogen (BIIB) Company Description: Incorporated in 1978, Massachusetts-based Biogen, Inc. is a biopharmaceutical company, which discovers, develops, and ...

Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

Biogen has a twelve month low of $173.14 and a twelve month high of $268.30. The company has a current ratio of 1.26, a quick ratio of 1.48 and a debt-to-equity ratio of 0.28. The stock has a 50 ...

Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...

Shares of Biogen Inc. BIIB slid 1.48% to $165.79 Wednesday, on what proved to be an all-around favorable trading session for ...

The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.80 and a current ratio of 1.26. Biogen Inc. has a one year low of $170.71 and a one year high of $268.30. The company has a ...

Biogen Pharmachem Industries Ltd was formerly incorporated as Wellworth Overseas Limited in July, 1995. The name of the Company was changed to Sun Techno Overseas Limited in August 2011 and again ...

If the pathway to Alzheimer’s diagnosis and treatment does not begin to improve rapidly, Biogen’s high-risk investment ... and we have a mixed view on the company's distribution strategy.

On Thursday, Biogen (NASDAQ:BIIB) experienced a change in its stock outlook as Morgan Stanley downgraded the company from Overweight to Equalweight. The financial institution also revised its ...